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INTRODUCTION 
The liver is one of the most vital parts of the body that 
has various functions, such as storage of sugars and 
glycogen, blood purification and the production of certain 
enzymes, which are essential for the life.
1 
Fatty liver is 
the most common liver disease worldwide, and the 
number of people with this disease is increasing in the 
world and in Iran.
2-5 
Fatty liver disease has not a 
symptom and is a silent disease which it is usually 
detected by referring to ultrasound for another illness or 
when it appears that affects the liver tissue and affects the 
normal functioning of the liver.
6
 
Prevention and self-care is essential for the prevention of 
fatty liver in non-infected people and its treatment and 
control for all people is very important. The first step in 
prevention of fatty liver and its control was to determine 
its risk factors.
7-11
 
The prevalence of this disease in general population was 
20 to 30 percent and according to the increasing risk 
factors of metabolic syndrome, this disease is one of the 
most common causes of liver disease in Western society. 
The causes of non-alcoholic fatty liver disease is 
unknown but many risk factors such as obesity, the 
amount of fat intake, the increase in body fat, 
hyperlipidemia, hypertension, type II diabetes, breast 
cancer, pregnancy, long hunger, and long-term use of 
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some medications, such as corticosteroids had main role 
in its occurrence.
4,8,9
 
The aim of this study was to investigate the prevalence of 
fatty liver and its risk factor in patients referred to 
Ardabil city hospital during 2015-2016. 
METHODS 
This cross-sectional descriptive study was conducted on 
80 patients with fatty liver disease that refered to the 
hospital of Ardabil city during 2015-2016. Necessary 
informations such as sex, age, degree of fatty liver, BMI, 
serum lipids, liver aminotransferases, serum uric acid and 
diabetes collected by a cheklist and then analyzed by 
statistical methods in SPSS.16. 
RESULTS 
Of all patients 32 (40%) were male and rest of them were 
female. The mean age of patients was 49.32±14.6 (range: 
23-81) and most of patients were in age group 40-49 
years with 31.3% (Figure 1). 
Hyperuricemia and diabetes was seen in 21.3% and 
38.8% of patients, respectively. 
 
Figure 1: Age distribuation of patients. 
 
Figure 2: The BMI status of patients. 
Of all patients 37 (46.2%) had overweight (25≤BMI≤30 
Kg/m
2
) (Figure 2). 
 
Figure 3: The status of grade of fatty liver in patients. 
The most grade of fatty liver in patients was grade 1 
which was seen in 43 (53.8%) of patients (Figure 3). 
 
Figure 4: The frequency of elevated levels of liver 
aminotransferases and bilirubin in patients. 
Of all patients 38.8% had ALT (Figure 4). 
 
Figure 5: The frequency of dislipidemia in patients. 
The high cholesterol was seen in 28 (35%) of patients 
(Figure 5). 
DISCUSSION 
In this study the mean age of patients was 49.32±14.6 
(range: 23-81) and 75% had age upper than 40 years. 
Shima and et al studied the effect of age and life style on 
the development and progression of the fatty liver and 
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showed that age had significant relation with non-
alcoholic steatohepatitis in fatty liver patients.
12
 
 In a study, Brea and Puzo reported that the prevalence of 
non-alchoholic fatty liver increase with age so that its 
prevalence increased to more than 40% in patients older 
than 60 years of age.
13
 
In a retrospective study by Frith and et al, there was a 
relation between age increasing and degree of fibrosis 
and also the non-alcoholic steatohepatitis and Cirrhosis in 
patients older than 50 years more prevalent than younger 
group.
14
 
In another study, age reported as a risk factor for Liver 
steatosis and also reported that patients with upper age 
have more probability to death and development of 
disease to fibrosis and hepatocellular carcinoma.
15
 
So we could say that the relation between age and fibrosis 
development in patients with non-alchholic fatty liver 
disease which can be related to long duration of disease 
in patients with older ages. The results of this study 
showed that 60% of patients were female and 40% were 
male and the frequency of fatty liver in female was 1.5 
times more than male. In totally, there were contradictory 
results in the relation between sex and non-alcholic fatty 
liver so that most of studies reported the higher rate of 
disease in male and some studies reported the higher rate 
of disease in female.
16
 
Similar to our study results, Stepanva and et al in a study 
showed that there wasn’t difference between rates of 
disease in male and female but non-alcoholic 
steatohepatitis in women was more than men.
17,18
 
Some studies showed that the gender male is a risk factor 
for non-alcoholic fatty liver and contradictory results can 
be due to study design and methods of diagnosis fatty 
liver.
15,9-22
 
In our study, only 18.8% of patients have normal weight 
and 81.2% had overweight or obesity.  
The BMI is a main risk factor for non-alcoholic fatty liver 
and in a study, the prevalence of non-alcoholic fatty liver 
in non obess people was 19.94% and obess people was 
75.05%.
23
 
The prevalence of non-alcoholic fatty liver was reported 
more than 90% in patients that candidated for obesity 
surgery. Of course, it should be noted that previous 
studies have shown that weight loss is associated with the 
relief of liver steatosis and other histological 
enhancements.
24-26
 
The importance of weight control was recommended for 
prevention of non-alcoholic fatty liver in obess and non-
obess people.
27,28
 
The results of this study showed that Alanine 
aminotransferase (ALT) in 38.8% of patients was upper 
than normal range and could say that in generally, the 
liver enzymes has relation with prevalence and 
development of non-alcoholic fatty liver. in some recent 
studies, increase in liver enzymes known as an invasive 
index in non-alcoholic fatty liver and these enzymes 
directly reflect the histological changes of the liver and 
the intensity of non-alcoholic fatty liver.
23,29-31
 
The high prevalence of dyslipidemia in patuents with 
fatty liver showed that the colestrol in 35% of patients, 
Glycerin in 50%  and low density lipoprotein (LDL) in 
17.5% of patients was upper than normal range. Also, 
results of this study showed that 21.3% of patients with 
fatty liver had Hyperuricemia. In line with our study, the 
result of a study showed that the high levels of uric acid, 
triglysirid, colestrol, LDL, HDL, ALT and AST are risk 
factors for fatty liver disease which independly relation 
with prevalence of diseae.
23
 
Hyperuricemia is a prevalent finding among non-
alcoholic fatty liver patients in recent studies and it was 
showed that independent of the status of insulin 
resistance and the metabolic syndrome of the patient, 
hyperuricemia had significant relation with histologic 
results in non-alcoholic fatty liver.
32
 
In current study, 38.8% of patients with fatty liver, had 
also diabetes and other studies have shown that diabetes 
and non-alcoholic fatty liver are closely interrelated.
33,34
 
Also a study has shown that type 2 diabetes is an 
independent predictor of non-alcoholic fatty liver.
35
 
CONCLUSION  
The results of this study showed that non-alcoholic fatty 
liver is more prevalent in female and older gae groups 
and abnormal finding such as obesity, ALT, dislipedimia, 
Hyperuricemia and diabetes is more prevalent in these 
patients and it seems that these factors play a major role 
in the development of non-alcoholic fatty liver and its 
prevalence in the society. 
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